(Q37973413)

26 August 2017

Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. (English)

1 reference

26 August 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

1

Lily P H Yang

1 reference

26 August 2017

1 January 2012

1 reference

26 August 2017

1 reference

26 August 2017

72

1 reference

26 August 2017

2

1 reference

26 August 2017

229-248

1 reference

https://scigraph.springernature.com/pub.10.2165/11208160-000000000-00000

26 August 2017

0 references

cites work

Management of type 2 diabetes: new and future developments in treatment

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Type 2 diabetes across generations: from pathophysiology to prevention and management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Global estimates of the prevalence of diabetes for 2010 and 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Mortality attributable to diabetes: estimates for the year 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Saxagliptin for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

The role of gut hormones in glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Combined thiazolidinedione-metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Linagliptin: in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Vildagliptin: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Alogliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Sitagliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208160-000000000-00000

Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

12 December 2020

Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects

1 reference

12 December 2020

Assessing the cardiovascular safety of diabetes therapies

1 reference

12 December 2020

Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin

1 reference

12 December 2020

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan

1 reference

12 December 2020

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

1 reference

12 December 2020

The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland

1 reference

12 December 2020

Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks

1 reference

12 December 2020

Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus

1 reference

12 December 2020

10.2165/11208160-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

22221000

Dimensions Publication ID

26 August 2017

0 references

1 reference

PubMed ID

22221000